Affiliations 

  • 1 Department of Pharmacy, Galgotias University, Greater Noida, Uttar Pradesh, India
  • 2 Department of Pharmacognosy, Faculty of Pharmacy, Tishk International University, Erbil 44001, Iraq
  • 3 Faculty of Pharmacy, AIMST University, Bedong 08100, Kedah, Malaysia
Curr Drug Deliv, 2023 Sep 05.
PMID: 37670704 DOI: 10.2174/1567201821666230905090621

Abstract

Drug discovery and development (DDD) is a highly complex process that necessitates precise monitoring and extensive data analysis at each stage. Furthermore, the DDD process is both time-consuming and costly. To tackle these concerns, artificial intelligence (AI) technology can be used, which facilitates rapid and precise analysis of extensive datasets within a limited timeframe. The pathophysiology of cancer disease is complicated and requires extensive research for novel drug discovery and development. The first stage in the process of drug discovery and development involves identifying targets. Cell structure and molecular functioning are complex due to the vast number of molecules that function constantly, performing various roles. Furthermore, scientists are continually discovering novel cellular mechanisms and molecules, expanding the range of potential targets. Accurately identifying the correct target is a crucial step in the preparation of a treatment strategy. Various forms of AI, such as machine learning, neural-based learning, deep learning, and network-based learning, are currently being utilised in applications, online services, and databases. These technologies facilitate the identification and validation of targets, ultimately contributing to the success of projects. This review focuses on the different types and subcategories of AI databases utilised in the field of drug discovery and target identification for cancer.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.